You are here

JUVARIS BIOTHERAPEUTICS, INC.

Company Information
Address
JUVARIS BIOTHERAPEUTICS, INC. 863A Mitten Road
BURLINGAME, CA 94010
United States



Information

UEI: N/A

# of Employees: N/A


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Immune Response Modification for Treatment of Hepatocellular Carcinoma

    Amount: $255,467.00

    DESCRIPTION (provided by applicant): Approximately 350 million people worldwide are chronic carriers of hepatitis B virus (HBV) and more than half of the hepatocellular carcinoma (HCC) cases worldwide ...

    SBIRPhase I2008Department of Health and Human Services National Institutes of Health
  2. Cationic Lipid/DNA/Antigen Complexes for Leukemia Vaccines

    Amount: $225,497.00

    DESCRIPTION (provided by applicant): The overall purpose of this project is to investigate and develop a novel vaccine for Acute Myelogenous Leukemia. This product, cationic lipid-DNA complexes (CLDC) ...

    SBIRPhase I2006Department of Health and Human Services National Institutes of Health
  3. Novel Immunostimulant/Adjuvant for HIV Vaccines: Non-Human Primate Studies

    Amount: $536,613.00

    DESCRIPTION (provided by applicant): The overall purpose of this proposal is to determine the level of innate and adaptive immune activation (i.e., anti-viral Th1 cytokines, antibody and cellular immu ...

    SBIRPhase I2006Department of Health and Human Services National Institutes of Health
  4. Innate Immune Stimulation as a Pathogen Countermeasure

    Amount: $975,860.00

    DESCRIPTION (provided by applicant): The overall purpose of this project is to investigate and develop a novel immune stimulant that can be used to elicit non-specific protection against pathogenic mi ...

    SBIRPhase I2006Department of Health and Human Services National Institutes of Health
  5. Lipid/DNA/Antigen Complexes for Influenza A Viral Vaccination

    Amount: $825,817.00

    DESCRIPTION (provided by applicant): Influenza A (fluA) infection causes annual substantial morbidity and mortality worldwide, particularly for infants, the elderly, and the immuncompromised. FluA mai ...

    STTRPhase I2006Department of Health and Human Services National Institutes of Health
  6. Lipid/DNA/Antigen Complexes for Influenza A Viral Vaccination

    Amount: $825,817.00

    DESCRIPTION (provided by applicant): Influenza A (fluA) infection causes annual substantial morbidity and mortality worldwide, particularly for infants, the elderly, and the immuncompromised. FluA mai ...

    SBIRPhase I2006Department of Health and Human Services National Institutes of Health
  7. Lipid/DNA/Antigen Complexes for Pseudomonas vaccines

    Amount: $164,619.00

    DESCRIPTION (provided by applicant): Juarez BioTherapeutics is developing and characterizing a unique adjuvant and stimulant of innate immunity based on the complexation of a cationic lipid carrier a ...

    SBIRPhase I2004Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government